Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled study to evaluate the efficacy of two different dose levels of orvepitant (10 and 30 mg) compared with placebo on EGFRi-induced intense pruritus in oncology subjects (The RELIEVE 1 Study)

Trial Profile

A randomised, double-blind, placebo-controlled study to evaluate the efficacy of two different dose levels of orvepitant (10 and 30 mg) compared with placebo on EGFRi-induced intense pruritus in oncology subjects (The RELIEVE 1 Study)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orvepitant (Primary)
  • Indications Pruritus
  • Focus Therapeutic Use
  • Acronyms RELIEVE-1
  • Sponsors NeRRe Therapeutics
  • Most Recent Events

    • 19 Dec 2015 According to European Clinical Trials Database record, status changed from active, no longer recruiting to discontinued.
    • 24 Jun 2015 Status changed from recruiting to active, no longer recruiting, as per UKCRN record.
    • 06 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top